Request Demo
Last update 17 Mar 2026
AZD-6750
Last update 17 Mar 2026
Overview
Basic Info
Drug Type Interleukins |
Synonyms AZD-6750 |
Target |
Action modulators, agonists |
Mechanism CD8 modulators(Cluster of differentiation 8 modulators), IL-2R agonists(Interleukin-2 receptor agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with AZD-6750NCT07115043
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
100 Clinical Results associated with AZD-6750
Login to view more data
100 Translational Medicine associated with AZD-6750
Login to view more data
100 Patents (Medical) associated with AZD-6750
Login to view more data
100 Deals associated with AZD-6750
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cutaneous Squamous Cell Carcinoma | Phase 2 | United States | 29 Jul 2025 | |
| Cutaneous Squamous Cell Carcinoma | Phase 2 | Japan | 29 Jul 2025 | |
| Cutaneous Squamous Cell Carcinoma | Phase 2 | Australia | 29 Jul 2025 | |
| Cutaneous Squamous Cell Carcinoma | Phase 2 | South Korea | 29 Jul 2025 | |
| Gastrooesophageal junction cancer | Phase 2 | United States | 29 Jul 2025 | |
| Gastrooesophageal junction cancer | Phase 2 | Japan | 29 Jul 2025 | |
| Gastrooesophageal junction cancer | Phase 2 | Australia | 29 Jul 2025 | |
| Gastrooesophageal junction cancer | Phase 2 | South Korea | 29 Jul 2025 | |
| high grade serous adenocarcinoma of ovary | Phase 2 | United States | 29 Jul 2025 | |
| high grade serous adenocarcinoma of ovary | Phase 2 | Japan | 29 Jul 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free